Cargando…

Can Urine Lamivudine Be Used to Monitor Antiretroviral Treatment Adherence?

Patient adherence to treatment is an important factor in the effectiveness of antiretroviral regimens. Adherence to treatment could be monitored by estimation of antiretroviral drugs in biological fluids. We aimed to obtain information on the quantity and duration of excretion of lamivudine in urine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kumar, Agibothu K Hemanth, Ramachandran, Geetha, Kumar, Periyaiyah, Kumaraswami, Vasanthapuram, Swaminathan, Soumya
Formato:	Texto
Lenguaje:	English
Publicado:	The International AIDS Society 2006
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2765995/ http://dx.doi.org/10.1186/1758-2652-8-4-53

Ejemplares similares

Food significantly reduces plasma concentrations of first-line anti-tuberculosis drugs
por: Kumar, Agibothu Kupparam Hemanth, et al.
Publicado: (2017)

Sub-therapeutic nevirapine concentration during antiretroviral treatment initiation among children living with HIV: Implications for therapeutic drug monitoring
por: Gopalan, Bindu Parachalil, et al.
Publicado: (2017)

Intrapatient variability in plasma rifampicin & isoniazid in tuberculosis patients
por: Kumar, A. K. Hemanth, et al.
Publicado: (2018)

Correlation between lamivudine plasma concentrations and patient self-reported adherence to antiretroviral treatment in experienced HIV patients
por: Minzi, OM, et al.
Publicado: (2011)

Role of pharmacogenomics in the treatment of tuberculosis: a review
por: Ramachandran, Geetha, et al.
Publicado: (2012)

Lack of association between plasma levels of non-nucleoside reverse transcriptase inhibitors & virological outcomes during rifampicin co-administration in HIV-infected TB patients
por: Ramachandran, Geetha, et al.
Publicado: (2013)

N-acetyltransferase gene polymorphisms & plasma isoniazid concentrations in patients with tuberculosis
por: Hemanth Kumar, A. K., et al.
Publicado: (2017)

Renal impairment after switching from stavudine/lamivudine to tenofovir/lamivudine in NNRTI-based antiretroviral regimens
por: Manosuthi, Weerawat, et al.
Publicado: (2010)

Environmental Risk Characterization of an Antiretroviral (ARV) Lamivudine in Ecosystems
por: Omotola, Elizabeth Oyinkansola, et al.
Publicado: (2021)

Abacavir/lamivudine combination in the treatment of HIV: a review
por: Sivasubramanian, Geetha, et al.
Publicado: (2010)

Emergence of Lamivudine-Resistant HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfected with HIV and HBV in China
por: Gu, Lijun, et al.
Publicado: (2015)

Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests
por: Swaminathan, Soumya, et al.
Publicado: (2016)

Dyslipidemia among HIV-infected Patients with Tuberculosis Taking Once-daily Nonnucleoside Reverse-Transcriptase Inhibitor–Based Antiretroviral Therapy in India
por: Padmapriyadarsini, Chandrasekaran, et al.
Publicado: (2011)

Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection
por: Deng, Lisi, et al.
Publicado: (2022)

Impact of Lamivudine-Based Antiretroviral Treatment on Hepatitis B Viremia in HIV-Coinfected South Africans
por: Lukhwareni, Azwidowi, et al.
Publicado: (2020)

Factors affecting high-density lipoprotein cholesterol in HIV-infected patients on nevirapine-based antiretroviral therapy
por: Padmapriyadarsini, C., et al.
Publicado: (2017)

Development and Validation of an Immunoassay for Tenofovir in Urine as a Real-Time Metric of Antiretroviral Adherence
por: Gandhi, Monica, et al.
Publicado: (2018)

Real-Time Adherence Monitoring for HIV Antiretroviral Therapy
por: Haberer, Jessica E., et al.
Publicado: (2010)

Lamivudine sensitivity - a case report
por: Budamakuntla, Leelavathy, et al.
Publicado: (2014)

Seven years of the field epidemiology training programme (FETP) at Chennai, Tamil Nadu, India: an internal evaluation
por: Bhatnagar, Tarun, et al.
Publicado: (2012)

SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients
por: Kumar, P, et al.
Publicado: (2010)

Dolutegravir–lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study
por: Cahn, Pedro, et al.
Publicado: (2017)

Evidence of Microbial Translocation Associated with Perturbations in T Cell and Antigen-Presenting Cell Homeostasis in Hookworm Infections
por: George, Palakkal Jovvian, et al.
Publicado: (2012)

What Can Urine Tell Us About Medication Adherence?
por: Anderson, Peter L.
Publicado: (2018)

Clinical Benefits and Cost-Effectiveness of Laboratory Monitoring Strategies to Guide Antiretroviral Treatment Switching in India
por: Freedberg, Kenneth A., et al.
Publicado: (2018)

Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV‐Coinfected Children in India: Recommendations for Dose Modifications
por: Guiastrennec, Benjamin, et al.
Publicado: (2018)

Hepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudine
por: Santos, Eneida A, et al.
Publicado: (2004)

Treatment of Hepatitis B Virus-Associated Membranous Nephropathy: Lamivudine Era versus Post-Lamivudine Era
por: Moon, Ju-Young, et al.
Publicado: (2012)

Clinical, Immunological and Virological Responses of Zidovudine-Lamivudine-Nevirapine versus Zidovudine-Lamivudine-Efavirenz Antiretroviral Treatment (ART) Among HIV-1 Infected Children: Asella Teaching and Referral Hospital, South-East Ethiopia
por: Sorsa, Abebe
Publicado: (2018)

Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection
por: Boffito, Marta, et al.
Publicado: (2020)

Week 120 Efficacy of Tenofovir, Lamivudine and Lopinavir/r-Based Second-Line Antiretroviral Therapy in Treatment-Experienced HIV Patients
por: Han, Yang, et al.
Publicado: (2015)

Characteristics of HBV infection in 705 HIV-infected patients under lamivudine-based antiretroviral treatment from three regions in China
por: Su, Mingze, et al.
Publicado: (2018)

Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B
por: Kim, Jeong Han, et al.
Publicado: (2014)

Lamivudine treatment for severe acute HBV hepatitis
por: Lisotti, Andrea, et al.
Publicado: (2008)

Tuberculosis in India - Can we ensure a test, treatment & cure for all?
por: Swaminathan, Soumya
Publicado: (2014)

Antiretroviral therapy adherence monitoring and its impact on immuno-virological outcome
por: Lobodan, Alina, et al.
Publicado: (2014)

Social media as a tool to monitor adherence to HIV antiretroviral therapy
por: Bychkov, David, et al.
Publicado: (2018)

361. Residual Lamivudine-Resistant Hepatitis B Virus Detected on Next-Generation Sequencing of Treatment-Experienced HIV Patients Failing Antiretrovirals
por: Schwem, Brian, et al.
Publicado: (2019)

Putative Repurposing of Lamivudine, a Nucleoside/Nucleotide Analogue and Antiretroviral to Improve the Outcome of Cancer and COVID-19 Patients
por: García-Trejo, José J., et al.
Publicado: (2021)

Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy – naive adults with HIV-1 infection
por: Cahn, Pedro, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l2knoh2ku2q245c497tp79d3se